What Acamprosate Calcium treats: main uses and benefits

Acamprosate Calcium is commonly used as pharmacotherapy for patients seeking to maintain continuous sobriety from alcohol. This medication is used in combination with counseling and social support to help people who have stopped drinking large amounts of alcohol avoid drinking again.

The primary therapeutic domain involves Alcohol Use Disorder (AUD), addressing symptoms relevant to maintenance of abstinence and relapse prevention. The medication is applied in addressing symptom clusters that may become intense or disruptive, specifically managing the persistent psychological and physical urges (cravings) for alcohol. This supportive role is considered relevant, as the pharmacological approach can provide support that helps ease the overall symptom burden, particularly the cravings that interfere with the goal of abstinence:

“The pharmacological approach can provide support that helps ease the overall symptom burden, particularly the powerful cravings that interfere with the goal of abstinence.”

Sustaining Abstinence and Easing Distress

The medication is commonly used across conditions characterized by periods of heightened symptoms to provide supportive therapeutic benefit to patients who are abstinent at the initiation of treatment. It is relevant in clinical settings that involve unstable symptom patterns, and plays a role in managing the risk of a relapse to support the goal of long-term sobriety. It contributes to improved day-to-day comfort during symptomatic periods, and supports patients during difficult episodes by easing distress.

Quick Fact: Relief for Alcohol Craving Acamprosate is commonly used to help with managing the intensity and frequency of alcohol urges, which supports patients during difficult episodes by easing distress.

Regulatory References

1. MedlinePlus Drug Information

Who Can and Cannot Use Acamprosate Calcium?

Acamprosate calcium is officially indicated for patients with alcohol dependence who have achieved abstinence prior to treatment initiation and are engaged in a comprehensive support program. Regulatory guidelines define specific populations who are restricted from using the medicine.

---

Absolute Contraindications

Use is contraindicated and prohibited in the following groups:

• Patients with severe renal impairment, defined as a creatinine clearance of leq 30 mL/min.
• Individuals with a known hypersensitivity or allergy to acamprosate calcium or any of its components.
• Lactating (breastfeeding) women (European labeling).

---

Age and Physiological Restrictions

Population Group	Eligibility Status	Restriction Basis
Adults (18–65)	Permitted	Established safety and efficacy.
Pediatric (Under 18)	Not Recommended	Safety and efficacy not established.
Geriatric (Over 65)	Not Recommended	Insufficient clinical data.
Moderate Renal Impairment	Restricted	Requires a mandatory dose reduction.
Pregnancy	Conditional Use	Allowed only if benefit justifies risk (Category C).

Efficacy has not been demonstrated in patients who have not achieved alcohol abstinence.

Acamprosate Calcium's interaction profile, as defined by official regulatory documentation, is characterized by a lack of significant metabolic interactions with many commonly co-administered medicines. The drug is minimally metabolized by the liver and is documented not to inhibit or induce the activity of major Cytochrome P450 enzymes (e.g., CYP3A4, 2D6).

No formal drug-drug combinations are listed as contraindicated. Clinical studies confirm the absence of significant pharmacokinetic or pharmacodynamic interactions when Acamprosate Calcium is co-administered with many psychotropic agents, including antidepressants, anxiolytics, hypnotics, sedatives, and non-opioid analgesics. Co-administration with Disulfiram, Diazepam, and Imipramine has also been found to be pharmacokinetically neutral.

A specific pharmacokinetic interaction is documented with Naltrexone, which increases the systemic exposure of Acamprosate by raising its Cmax and AUC. Despite this measurable increase, regulatory agencies state that no adjustment to the Acamprosate Calcium dosage is required.

Furthermore, the concomitant intake of alcohol (ethanol) does not affect the drug's pharmacokinetics. Administration with food diminishes the oral bioavailability of Acamprosate. The single most important interaction-related restriction is the contraindication of its use in patients with severe renal impairment (CrCl le 30 mL/min). This restriction is necessary because the drug is primarily eliminated by the kidneys, and impairment leads to a high risk of accumulation.

How Acamprosate Calcium Works

Acamprosate calcium exerts its pharmacodynamic effects primarily through the central nervous system, focusing on the regulation of two major neurotransmitter systems: glutamate (excitatory) and gamma-aminobutyric acid (GABA, inhibitory).

Within the glutamatergic system, the compound functions as a partial N-methyl-D-aspartate ( NMDA) receptor modulator, predominantly influencing activity at specific receptor subtypes. This interaction dampens excessive postsynaptic excitability mediated by glutamate. Concurrently, Acamprosate engages the GABA system, acting to modulate inhibitory neurotransmission. This dual activity on the excitatory and inhibitory pathways influences the dynamic equilibrium within neural circuits.

This results in the modification of molecular steps associated with heightened neural activity and excessive mediator release. The overall systemic physiological consequence is the regulation of synaptic homeostasis by adjusting the ratio between neuronal excitation and inhibition.

How to use Acamprosate Calcium

Acamprosate calcium is administered exclusively via the oral route as a delayed-release tablet (gastro-resistant). The specialized enteric coating dictates that the tablets must be swallowed whole and must not be crushed or chewed to ensure correct absorption in the intestine as intended by the formulation.

The standard adult dosing regimen is a total of 1998 mg per day. This is achieved by taking two 333 mg tablets, for a dose of 666 mg, three times daily (TID). Taking the tablets with meals is an accepted practice to assist patients with adherence to the three-times-daily schedule.

Treatment Course and Timing

Usage is structured as a component of a comprehensive management program that includes psychosocial support. Treatment initiation is required after the patient has achieved abstinence from alcohol. The standard duration for the treatment course is generally recommended to be one year. If a patient relapses to alcohol use during the course, the treatment should be maintained.

---

Population-Specific Administration

Dosing adjustments are necessary based on kidney function. In the case of moderate renal impairment (creatinine clearance 30–50 mL/min), the total daily dose is reduced to 999 mg, administered as one 333 mg tablet three times daily. The medication is not to be administered in cases of severe renal impairment (creatinine clearance less than or equal to 30 mL/min). If a dose is missed, patients should resume the regimen with the next scheduled dose and should not take extra tablets to compensate for the missed one.

Research Evidence / Overview of Studies

---

Short-Term Efficacy Studies

Research explored Acamprosate's impact on short-term symptom reporting in individuals with alcohol dependence.

A pivotal Phase 2 trial investigated the effects of the treatment over a 4-week period. The primary endpoint was a change in the self-reported abstinence or drinking scores from baseline. The study design focused on patients who had recently achieved sobriety. The findings were used to establish the initial dosing parameters for later-stage trials.

A key meta-analysis evaluated findings related to abstinence rates. This analysis included data from multiple randomized controlled trials (RCTs) involving a large number of participants in total. The analysis reported on the overall average change in the rate of continuous abstinence across these combined studies.

Dose-Ranging and Long-Term Data

Studies investigated whether various doses of Acamprosate led to a change in abstinence or relapse symptoms.

Phase 3 studies evaluated the use of the drug over 6- to 12-month periods to assess long-term response. These trials examined whether standard daily doses were associated with different outcomes regarding the frequency of heavy drinking or relapse to alcohol use. The data from these studies contribute to the understanding of the drug’s long-term profile.

Research evaluated the study findings and compared the reported outcomes to placebo. This comparison was part of controlled trials designed to determine if the drug’s performance was statistically different from an inactive substance.

The studies focused primarily on adults who had completed detoxification and were motivated to maintain abstinence.

Studies on Combination Therapy

Studies explored whether Acamprosate, when combined with psychosocial support, was associated with changes in long-term outcomes.

One study investigated the possible additive effects when the drug was administered alongside behavioral counseling. The research design examined whether the combined regimen was associated with a greater change in relapse prevention rates compared to either treatment alone.

The Phase 3 trials reported on all measured outcomes and safety events. This included a comprehensive review of all reported adverse events and the rate of discontinuation across the treatment groups.

Key Studies & References

1. Efficacy of Acamprosate and Disulfiram in the Treatment of Alcohol Dependence: A Comparative Clinical Trial

Common questions about Acamprosate Calcium (FAQ)

---

Q: How is Acamprosate Calcium different from other medications used for the same purpose?

Regulatory documents describe that Acamprosate has a distinct profile compared to some other medicines used for similar purposes. It is reported to be minimally metabolized by the liver. Furthermore, official information indicates that it is not documented to have significant interactions with opioid pain medications.

Q: How is the timing of the effect described for Acamprosate Calcium?

Studies on the drug’s absorption and metabolism indicate that steady-state concentrations in the bloodstream are reported to be reached within about five days of starting the medication. The full intended effect is generally associated with steady-state concentrations being reached within 5 to 8 days of treatment.

Q: Will I feel the full effects of the medicine immediately?

No. The medication is described as reaching its full intended effect gradually. Official pharmacokinetic information indicates that the full intended effect is generally associated with steady-state concentrations being reached within 5 to 8 days of consistent treatment.

Q: Are there official descriptions of what to do if a minor side effect occurs?

Official patient information describes the recommendation to speak with their doctor or pharmacist if they experience any side effects. This guidance applies particularly if side effects are bothersome, persistent, or cause concern.

Q: Does the time of day the medicine is taken matter, based on official instructions?

The standard dosing schedule is administered three times daily, usually taken in the morning, at noon, and in the evening to assist with consistent dosing. This schedule helps maintain consistent levels as part of the overall regimen.

Q: What is the official guidance on taking Acamprosate Calcium with or without food?

Official documents state that while taking the tablets with food may slightly decrease the amount of medicine absorbed into the body, this decrease is not considered clinically significant. It can be taken with or without food, though taking it with meals may assist patients with adherence to the three-times-daily schedule.

Q: Can Acamprosate Calcium be taken during pregnancy, according to official classification?

The medication is classified as Pregnancy Category C in the U.S. This classification indicates that use is conditional, typically reserved for when a healthcare professional determines the potential treatment benefit outweighs the possible risk to the fetus.

Q: What are the most commonly reported side effects in clinical trials?

The most frequently reported side effect in clinical trials is diarrhea, which is classified as very common (affecting 1 in 10 people or more). Other common side effects include abdominal pain, nausea, anxiety, depression, insomnia, and asthenia (weakness).

Q: What is the safety profile of Acamprosate Calcium in people with a history of seizures?

Official studies have not documented the medication to possess anticonvulsant activity (the ability to prevent seizures). Regulatory warnings do not list seizures or epilepsy as a contraindication or common adverse reaction.

Q: Are there any food restrictions while taking Acamprosate Calcium?

Because treatment is intended to support abstinence from alcohol, official patient information advises against using alcohol-containing foods or products. This may include certain sauces, vinegars, or other items containing small amounts of alcohol.

Q: Is Acamprosate Calcium approved for use in people under the age of 18?

The safety and effectiveness of Acamprosate Calcium have not been established for use in pediatric patients (individuals under 18 years of age).

Q: Are there any specific safety concerns for older adults using Acamprosate Calcium?

The use of the drug is generally not recommended for adults over 65 due to insufficient clinical data in this age group. However, a specific concern is that older adults are more likely to have reduced kidney function, which may necessitate a dosage adjustment.

Q: Is Acamprosate Calcium known to be habit-forming?

Official documents indicate that in both animal studies and human clinical experience, the administration of Acamprosate Calcium has not been associated with the development of tolerance or dependence.

Q: What should a patient generally know about stopping Acamprosate Calcium?

Regulatory guidance describes the recommendation that patients should not discontinue use or change the dosage without consulting their healthcare professional. Any decision to modify the regimen should be determined in consultation with them.

Q: Do studies suggest that Acamprosate Calcium is more effective for certain groups of people?

Research has indicated that the medication may be more effective for a specific subgroup of patients. This includes individuals who are highly motivated to achieve and maintain complete abstinence from alcohol.

Q: Is Acamprosate Calcium taken to reduce cravings?

Yes, the main therapeutic goal of the medication is to reduce the intensity of psychological and physical urges, or cravings, for alcohol. This is intended to support the patient in maintaining long-term abstinence after they have stopped drinking.

Q: Are there official documents on whether this drug causes weight gain or loss?

The official adverse event listings include anorexia (loss of appetite) as a reported side effect. Anorexia has been reported in clinical trials at a rate of less than 5%.

Q: Can Acamprosate Calcium cause allergic reactions, and what are the signs to look for?

The medication carries a warning regarding the possibility of very rare severe hypersensitivity reactions (allergic reactions). Official information lists warning signs such as swelling of the face, lips, tongue, or throat, hives, or difficulty breathing.

Q: Is there any research on long-term effects of taking Acamprosate Calcium?

The standard duration of the pivotal clinical trials was between six months and one year. Official reviews have noted a lack of robust clinical data on the effectiveness and safety profile of taking the medication for continuous periods exceeding one year.

Q: Does Acamprosate Calcium require a special prescription or monitoring?

This medication is only available with a doctor's prescription. Official warnings advise that patients should be monitored by a healthcare professional for the potential development of symptoms of depression or suicidal thinking.

Q: Why is Acamprosate Calcium typically used as part of a larger treatment program?

Official prescribing information states that the drug is approved specifically for use as part of a comprehensive management program. This program is defined as one that includes the use of psychosocial support, such as counseling.

Q: Is Acamprosate Calcium mentioned in major international guidelines for alcohol treatment?

Yes, the use of Acamprosate is recognized and recommended by major international and national guidelines. These include the UK’s National Institute for Health and Care Excellence (NICE) and certain guidelines from the U.S. Department of Veterans Affairs.

Q: What is the typical timeframe for initial follow-up appointments after starting the medication?

Clinical trial protocols have typically shown patient visits occurring more frequently during the initial treatment phase. This frequency has been described as often as every one to two weeks during the beginning stages of the study.

Q: Are there any specific warnings about driving or operating machinery while on Acamprosate Calcium?

Patients are advised to use caution when driving or operating hazardous machinery, as the medication may affect coordination, reaction time, or judgment.

Q: How does Acamprosate Calcium compare to a placebo in clinical research?

Research, including meta-analyses that combine multiple studies, has concluded that Acamprosate Calcium is statistically more effective than a placebo. Reported findings include an increase in both the rate and the duration of continuous abstinence from alcohol.

Q: Are there differences in the patient experience reported across various studies?

Official reviews of the clinical trials have noted that the reported outcomes and efficacy results have shown variation between studies. This variability has been observed particularly when comparing outcomes between trials conducted in the U.S. and those conducted in Europe.

Q: Do official materials describe Acamprosate Calcium as working immediately or gradually?

Official materials describe the drug as working gradually, with steady-state concentrations reached within about five days. The full intended effect is generally associated with steady-state concentrations being reached within 5 to 8 days of consistent treatment.

Storage and Disposal for Acamprosate Calcium

Acamprosate calcium delayed-release tablets must be stored at Controlled Room Temperature (CRT), which is 20 C to 25 C (68 F to 77 F). The official label permits temperature excursions between 15 C and 30 C (59 F and 86 F). The product must be kept in a closed container and protected from freezing, heat, moisture, and direct light to maintain stability.

---

Handling and Safety

To prevent accidental ingestion, the medication must be stored out of the sight and reach of children.

For disposal of any unused or expired tablets, individuals are instructed to ask a healthcare professional for guidance. This ensures proper handling and avoids discarding the medication into household waste or wastewater.